ArticleTransplantation and cellular therapy2025

Validation of Cure Assumptions when Analyzing ZUMA-7 Follow-up Data of Axicabtagene Ciloleucel and Standard of Care Therapy in Second-Line Relapsed/Refractory Large B-cell Lymphoma.

Miguel-Angel Perales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.